Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Liabilities and Shareholders Equity Other Accumulated Expenses Other Non-Current Assets Payables Prepaid Assets Receivables Retained Earnings Shareholder's Equity Short-term Investments Total Current Liabilities Total Liabilities

Daily Values

Growth Metrics

Income Statement

Others

Ratios

Anbio Biotechnology (NNNN) Non-Current Assets (2023 - 2024)

Anbio Biotechnology has reported Non-Current Assets over the past 2 years, most recently at $387440.0 for Q4 2024.